1. Scrip

Janux Has A License To Thrill With 007’s Prostate Cancer Results

 
• By Andrew McConaghie

The masked T-cell engager has produced eye-catching results in heavily pre-treated prostate cancer patients, and Janux is aiming to jump ahead of Novartis’s Pluvicto in treatment regimens.

Prostate cancer
CellCentric says it has a first-in-class prostate cancer therapy • Source: Shutterstock

Janux Therapeutics has generated great excitement with its prostate cancer treatment, JANX007, with analysts hailing updated Phase I results as showing potential best-in-class safety and efficacy.

Like its secret agent namesake, JANX007 is designed to be a highly targeted killer: the ‘masked’ T-cell engager triggers the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Scrip

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.